MorphoSys Aktie
| 67,80EUR | -0,65EUR | -0,95% |
WKN: 663200 / ISIN: DE0006632003
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Novartis AG | 51,00 |
| Freefloat | 48,96 |
| Adage Capital Management LP | 5,01 |
| Armistice Capital LLC | 4,69 |
| Norges Bank Investment Management | 4,48 |
| RP Management LLC (Investment Management) | 3,55 |
| Government Pension Fund - Global (The) | 2,91 |
| Goldman Sachs & Co. LLC (Private Banking) | 2,88 |
| Caligan Partners LP | 2,81 |
| DWS Investment GmbH | 2,30 |
| Baillie Gifford & Co. | 2,21 |
| Vanguard International Growth Fund | 1,76 |
| Lupus alpha Fonds - Smaller German Champions | 0,85 |
| Delaware Healthcare Fund | 0,80 |
| DekaFonds CF/TF | 0,69 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 426 | 615 | 732 | 647 | 564 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,17 | 0,53 | 0,25 | 0,43 | 0,42 |
Bilanz (in Mio. EUR) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 304 | 1 207 | 1 133 | 1 089 | 814 |
| Summe Anlagevermögen | 193 | 453 | 1 423 | 1 308 | 1 212 |
| Summe Aktiva | 496 | 1 660 | 2 556 | 2 397 | 2 026 |
Bilanz (in Mio. EUR) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 43 | 318 | 326 | 339 | 258 |
| Summe Fremdkapital | 102 | 1 038 | 2 311 | 2 240 | 1 977 |
| Summe Eigenkapital | 395 | 621 | 245 | 157 | 49 |
| Summe Passiva | 496 | 1 660 | 2 556 | 2 397 | 2 026 |
Adresse
| Semmelweisstrasse 7, 82152 Planegg | |
| Telefon | +49 (89) 89927-0 |
| Fax | +49 (89) 89927-222 |
| Internet | http://www.morphosys.de |
Management
|
Ann Merchant
Vice President & Head-Global Supply Chain |
|
Arkadius Pichota
Chief Executive Officer |
|
Barbara Krebs-Pohl
Chief Business Officer |
|
Charlotte Lohmann
Chief Legal & Human Resources Officer |
|
Daniel Palmacci
President-Lonzas Cell & Gene Division |
|
Günter Wellnhofer
Head-Facilities |
|
Heinrich Moisa
Member-Supervisory Board |
|
Julia Neugebauer
Vice President-Global Investor Relations |
|
Klaus de Wall
Head-Accounting & Tax |
|
Luisa Ciccarelli
Senior VP & Global Head-Technical Operations |
|
Lukas Gilgen
Chief Financial Officer |
|
Ralf Ostendorp
Senior Vice President, Head-Protein Sciences & CMC |
|
Romain Lege
Member-Supervisory Board |
|
Silke Mainka
Member-Supervisory Board |
|
Tim Demuth
Chief Research & Development Officer |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
